Åsa Gylfe

Jag forskar om att hitta små molekyler som kan utvecklas till nya läkemedel mot infektioner. Specifikt fokuserar jag på molekyler som har effekt på klamydiabakterier.

Vetenskaplig meritering: Docent

Pedagogisk meritering: Meriterad lärare

0000-0001-8632-7087

Kontakt

asa.gylfe@umu.se

090-785 11 26

Verksam vid

Universitetslektor, specialistutbildad läkare vid Institutionen för klinisk mikrobiologi Enhet: Klinisk bakteriologi, Avdelningen för infektion och immunologi

By 6 B, Klin bakteriologi, Universitetssjukhuset Umeå universitet, 901 85 Umeå

Varje år drabbas mer än 100 miljoner människor i världen av en sexuellt överförd klamydiainfektion och nästan lika många behandlas för trakom, en klamydiainfektion i ögonen som kan förstöra synen. Infektionerna behandlas med antibiotika som också har effekt mot andra bakterier och driver fram antibiotikaresistens hos andra sjukdomsframkallande bakterier. Antibiotikaresistens uppstår även hos klamydiabakterier och i framtiden kan dagens antibiotika bli mindre verksamma mot klamydiainfektioner.

Målet med min forskning är att hitta små molekyler som kan utvecklas till nya läkemedel mot infektioner. Specifikt fokuserar jag på molekyler som har effekt på klamydiabakterier. Projektet kan på lång sikt leda fram till nya behandlingsalternativ för klamydiainfektioner och även för andra infektioner, samtidigt minska resistensutveckling och förhindra globalt förekommande invalidiserande sjukdomar.

Prediagnostic prescription antibiotics use and survival in patients with colorectal cancer: a swedish national register-based study

Cancer Epidemiology, Biomarkers and Prevention, American Association For Cancer Research (AACR) 2023, Vol. 32, (10) : 1391-1401

Lu, Sai San Moon; Rutegård, Martin; Ahmed, Maghfoor; et al.

Changes in testing and incidence of Chlamydia trachomatis and Neisseria gonorrhoeae: the possible impact of the COVID-19 pandemic in the three Scandinavian countries

Infectious Diseases, Taylor & Francis 2022, Vol. 54, (9) : 623-631

Ivarsson, Lovisa; de Arriba Sánchez de la Campa, Magdalena; Elfving, Karin; et al.

Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study

Journal of the National Cancer Institute, Oxford University Press 2022, Vol. 114, (1) : 38-46

Lu, Sai San Moon; Mohammed, Zahraa; Häggström, Christel; et al.

Modified Fluoroquinolones as Antimicrobial Compounds Targeting Chlamydia trachomatis

International Journal of Molecular Sciences, MDPI 2022, Vol. 23, (12)

Vu, Thi Huyen; Adhel, Erika; Vielfort, Katarina; et al.

High prevalence of pharyngeal bacterial pathogens among healthy adolescents and young adults

Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), John Wiley & Sons 2021, Vol. 129, (12) : 711-716

Agerhäll, Martin; Henrikson, Martin; Johansson Söderberg, Jenny; et al.

A 2-pyridone amide inhibitor of transcriptional activity in Chlamydia trachomatis

Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2021, Vol. 65, (5)

Núñez-Otero, Carlos; Bahnan, Wael; Vielfort, Katarina; et al.

Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis

Journal of Fungi, MDPI 2020, Vol. 6, (4)

Risum, Malene; Helweg-Larsen, Jannik; Petersen, Soren Lykke; et al.

Methyl sulfonamide substituents improve the pharmacokinetic properties of bicyclic 2-pyridone based Chlamydia trachomatis inhibitors

MedChemComm, Royal Society of Chemistry 2019, Vol. 10, (11) : 1966-1987

Kulén, Martina; Núñez-Otero, Carlos; Cairns, Andrew G.; et al.

Phospholipid Levels in Blood during Community-Acquired Pneumonia

PLOS ONE, Public Library of Science 2019, Vol. 14, (5)

Müller, Daniel C.; Kauppi, Anna; Edin, Alicia; et al.

Mosquitoborne Sindbis Virus Infection and Long-Term Illness

Emerging Infectious Diseases, Centers for Disease Control and Prevention (CDC) 2018, Vol. 24, (6) : 1141-1142

Gylfe, Åsa; Ribers, Åsa; Forsman, Oscar; et al.

Red Fluorescent Chlamydia trachomatis Applied to Live Cell Imaging and Screening for Antibacterial Agents

Frontiers in Microbiology, Frontiers Media S.A. 2018, Vol. 9

Mojica, Sergio; Eriksson, Anna U.; Davis, Rohan A.; et al.

Natural product inspired library synthesis – Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis

European Journal of Medicinal Chemistry, Elsevier 2018, Vol. 143 : 1077-1089

Saleeb, Michael; Mojica, Sergio; Eriksson, Anna U.; et al.

Thiazolino 2-pyridone amide isosteres as inhibitors of Chlamydia trachomatis infectivity

Journal of Medicinal Chemistry, American Chemical Society (ACS) 2017, Vol. 60, (22) : 9393-9399

Good, James A. D.; Kulén, Martina; Silver, Jim; et al.

Melioidos: en viktig diagnos vid svår sjukdom efter utlandsresa

Läkartidningen, Stockholm: Läkartidningen Förlag AB 2017, Vol. 114, (41)

Gylfe, Åsa; Cajander, Sara; Wahab, Tara; et al.

N-acylated derivatives of sulfamethoxazole block Chlamydia fatty acid synthesis and interact with FabF

Antimicrobial Agents and Chemotherapy, American society for microbiology 2017, Vol. 61, (10)

Mojica, Sergio A.; Salin, Olli; Bastidas, Robert J.; et al.

Thiazolino 2-Pyridone Amide Inhibitors of Chlamydia trachomatis Infectivity

Journal of Medicinal Chemistry, American Chemical Society (ACS) 2016, Vol. 59, (5) : 2094-2108

Good, James A. D.; Silver, Jim; Núñez-Otero, Carlos; et al.

Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room

PLOS ONE, Vol. 11, (1)

Kauppi, Anna M.; Edin, Alicia; Ziegler, Ingrid; et al.

Detection and Isolation of Sindbis Virus from Mosquitoes Captured During an Outbreak in Sweden, 2013

Vector Borne and Zoonotic Diseases, Vol. 15, (2) : 133-140

Bergqvist, Joakim; Forsman, Oscar; Larsson, Pär; et al.

Design, synthesis and evaluation of novel polypharmacological antichlamydial agents

European Journal of Medicinal Chemistry, Vol. 101 : 595-603

Sunduru, Naresh; Salin, Olli; Gylfe, Åsa; et al.

Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner

Journal of Bacteriology, American Society for Microbiology 2014, Vol. 196, (16) : 2989-3001

Bao, Xiaofeng; Gylfe, Åsa; Sturdevant, Gail L.; et al.

Inhibitory Activity of the Isoflavone Biochanin A on Intracellular Bacteria of Genus Chlamydia and Initial Development of a Buccal Formulation

PLOS ONE, Vol. 9, (12)

Hanski, Leena; Genina, Natalja; Uvell, Hanna; et al.

N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis

Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2014, Vol. 58, (5) : 2968-2971

Marwaha, Sania; Uvell, Hanna; Salin, Olli; et al.

Mutations in hemG Mediate Resistance to Salicylidene Acylhydrazides, Demonstrating a Novel Link between Protoporphyrinogen Oxidase (HemG) and Chlamydia trachomatis Infectivity

Journal of Bacteriology, Washington DC, USA: American Society for Microbiology 2013, Vol. 195, (18) : 4221-4230

Engström, Patrik; Nguyen, Bidong D.; Normark, Johan; et al.

Derivatives of 8-hydroxyquinoline-antibacterial agents that target intra- and extracellular Gram-negative pathogens

Bioorganic & Medicinal Chemistry Letters, Elsevier 2012, Vol. 22, (10) : 3550-3553

Enquist, Per-Anders; Gylfe, Åsa; Hägglund, Ulrik; et al.

The isoflavone biochanin a inhibits the growth of the intracellular bacteria Chiamydia trachomatis and Chlamydia pneumoniae

Planta Medica, Georg Thieme Verlag KG 2012, Vol. 78, (11) : 1102-1102

Pohjala, L.; Uvell, Hanna; Hakala, E.; et al.

Preliminary pharmacokinetics of the bacterial virulence inhibitor N'-(3,5-dibromo-2-hydroxy-benzylidenene)-nicotinic acid hydrazide

Advances in Yersinia Research, Springer 2012 : 349-356

Ur-Rehman, Tofeeq; Nordfelth, Roland; Blomgren, Anders; et al.

Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion

The Journal of antibiotics, Vol. 65 : 397-404

Ur-Rehman, Tofeeq; Slepenkin, Anatoly; Chu, Hencelyn; et al.

Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia

Bioorganic & Medicinal Chemistry, Vol. 18, (7) : 2686-2703

Dahlgren, Markus K; Zetterström, Caroline E; Gylfe, Åsa; et al.

Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report.

Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 29, (10) : 1478-1480

Ovchinnikova, Olga; Gylfe, Åsa; Bailey, Leslie; et al.

Pathogen burden and cortisol profiles over the day

Epidemiology and Infection, New York: Cambridge University Press 2009, Vol. 137, (12) : 1816-1824

Steptoe, A; Gylfe, Åsa; Shamaei-Tousi, A; et al.

Role of birds in the biology of Lyme disease Borrelia

Umeå University medical dissertations, N.S., 740

Gylfe, Åsa

Isolation of Lyme disease Borrelia from puffins (Fratercula arctica) and seabird ticks (Ixodes uriae) on the Faeroe Islands

Journal of Clinical Microbiology, Vol. 37, (4) : 890-896

Gylfe, Åsa; Olsen, Björn; Strasevicius, Darius; et al.

Small molecule inhibitors reveal a role for the Chlamydia type III secretion system in iron acquisition

Bailey, Leslie; Muschiol, Sandra; Engström, Patrik; et al.

Antibiotics use up to 4.5 years before colorectal cancer surgery is associated with an elevated risk of surgical site infections, including anastomotic leakage, particularly in colon cancer: a Swedish nationwide study

Lu, Sai San Moon; Rutegård, Martin; Häggström, Christel; et al.

Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion

Ur-Rehman, Tofeeq; Blomgren, Anders; Elofsson, Mikael; et al.

Visa publikationer i DiVA

Forskargrupper

Forskningsledare

Åsa Gylfe Lab

Publicerad: 01 dec, 2017

38 forskare får ALF-medel

Filmade föreläsningar

Vetenskapslunch:

Åsa Gylfe: Den spännande jakten på ny antibiotika